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Dynamic clamp, a hybrid-computational-experimental technique that has been used
to elucidate ionic mechanisms underlying cardiac electrophysiology, is emerging as a
promising tool in the discovery of potential anti-arrhythmic targets and in pharmacological
safety testing. Through the injection of computationally simulated conductances into
isolated cardiomyocytes in a real-time continuous loop, dynamic clamp has greatly
expanded the capabilities of patch clamp outside traditional static voltage and
current protocols. Recent applications include fine manipulation of injected artificial
conductances to identify promising drug targets in the prevention of arrhythmia and the
direct testing of model-based hypotheses. Furthermore, dynamic clamp has been used
to enhance existing experimental models by addressing their intrinsic limitations, which
increased predictive power in identifying pro-arrhythmic pharmacological compounds.
Here, we review the recent advances of the dynamic clamp technique in cardiac
electrophysiology with a focus on its future role in the development of safety testing and
discovery of anti-arrhythmic drugs.
Keywords: dynamic clamp, cardiac electrophysiology, cardiac modeling, arrhythmia mechanisms, antiarrhythmic
drugs, pharmacology & drug discovery
INTRODUCTION
The search for successful anti-arrhythmia therapeutics is rooted in the voltage clamp and current
clamp techniques, which have provided the mechanistic details behind the ionic membrane
currents that compose the cardiac action potential (AP). While basic science has made great
leaps in identifying and characterizing the basic factors involved in arrhythmia, the translation
of these advances into successful therapies has been lackluster. Nonetheless, investigators have
been using a combination of experimental and computational approaches to unravel the complex
mechanisms underlying cardiac arrhythmia. Using this approach, experimental measurements,
typically in single cells from mammalian hearts, are used to develop biophysically detailed
mathematical models that can be scaled up to the tissue and whole-organ levels where
arrhythmia occurs. Unlike experiments, computational modeling readily allows for the precise
perturbation of particular parameters individually or in controlled combinations (simulating,
e.g., the multifactorial nature of many disorders), but results are reliant on the accuracy of the
model and its many components. The dynamic clamp technique is a merger between experimental
and computational techniques that has been gaining traction as a hybrid method for elucidating
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arrhythmia mechanisms and possible therapeutics.
Traditional patch clamp protocols are typically static and
predetermined, such as sequential voltage steps used to study
membrane current dependencies. Dynamic clamp is an extension
of patch clamp, where measurements from the cell are used
to modify a continuously changing experimental protocol in
a real-time feedback loop (Robinson and Kawai, 1993; Sharp
et al., 1993). Earlier work has shown broad application—coupling
of separate cardiomyocytes through an artificial gap junction
(Tan and Joyner, 1990; Joyner et al., 1991; Spitzer et al., 1997;
Verheijck et al., 1998; Zaniboni et al., 2000; Huelsing et al.,
2001), injection of measured current from a transfected cell
into a primary isolated myocyte (Berecki et al., 2005, 2006),
antrhomorphization of mouse cardiac APs (Ahrens-Nicklas and
Christini, 2009; Bot et al., 2012), and more recently in the
study of cardiomyocyte coupling to unexcitable cells (McSpadden
et al., 2012) and fibroblasts/myofibroblasts (Nguyen et al., 2012;
Brown et al., 2016). The history of dynamic clamp has been
reviewed in detail elsewhere (Prinz et al., 2004; Wilders, 2006;
Ravagli et al., 2016). Here, we focus on a specific configuration
of this technique, called the dynamic model clamp (referred
hereafter as dynamic clamp), where a mathematically based
model of a conductance is injected to the cell in real-time.
Characteristically, this mathematical model describes a specific
voltage and time-dependent membrane current determined by a
set of differential equations. Measured voltage of a cell in a patch
clamp configuration is fed into a mathematical model at high
rates, from which the calculated current is injected back into the
cell (Figure 1A).
Central to the dynamic clamp experimental rig is the software,
which acts as the interface between the patch-clamp hardware
and mathematical models. Accurate and rapid sampling of the
membrane potential and computation of the virtual conductance
is required to mimic sufficiently a biological conductance
(Bettencourt et al., 2008). These requirements necessitate hard
real-time control. In this context, the feedback loop must
complete every iteration within a specified time constraint,
typically 50–100 µs (10–20 kHz) in cardiomyocyte dynamic
clamp experiments, a feat not possible on standard operating
systems and software due to technical limitations. The works
discussed here predominately use two software platforms—
DynaClamp (Berecki et al., 2005, 2006) and the Real-Time
eXperimental Interface (RTXI, www.rtxi.org; Ortega et al., 2014;
Patel et al., 2017). Both platforms utilize a customized real-time
Linux operating system and are freely available.
In this review, we discuss how investigators have used the
dynamic clamp technique to test theoretical drug targets, validate
and improve existing cardiac mathematical models, and design
assays for cardiotoxicity testing.
INVESTIGATION OF ARRHYTHMIA
MECHANISMS
Drug Target Identification
Dynamic clamp studies on the cardiac L-type Ca2+ current
(ICaL) by Madhvani et al. identified arrhythmia mechanisms,
which could potentially be targeted by anti-arrhythmic drugs
(Madhvani et al., 2011, 2015). The authors specifically focused
on the role of ICaL in the formation of early after depolarizations
(EADs), i.e., secondary depolarizations during phase 2 and 3 of
the AP resulting from a transient failure of AP repolarization.
EADs are used as a marker of cardiac arrhythmia due to its
propensity to trigger a premature AP and subsequently initiate
cardiac arrhythmias, such as Torsades de pointes (TdP) or
ventricular fibrillation, which in turn can lead to sudden cardiac
death (Cranefield and Aronson, 1991). EADs require an inward
current that can overcome and reverse repolarization, which can
be fulfilled by ICaL, the major inward current during phase 2 and
3 of the AP. Madhvani et al. aimed to investigate the dependence
of EADs on the biophysical properties of ICaL, but the lack of
an assortment of drugs known to finely alter this current makes
traditional patch clamp experiments impractical. Thus, to mimic
theoretical perturbations to ICaL properties in vitro dynamic
clamp was used instead.
In rabbit ventricular myocyte exhibiting EADs, induced with
either hydrogen peroxide (Figure 1B, top) or hypokalemia,
they replaced native ICaL (blocked with nifedipine) with a
virtual model-based ICaL, which was injected using dynamic
clamp (Figure 1B, middle). The consequences of alterations in
ICaL biophysical properties were investigated by manipulating
the parameters underlying the modeled current. For example,
shifting the half-maximal activation voltage by 5mV abolished
EADs and returned AP duration (APD) to normal values
(Figure 1B, bottom). Note that H2O2 affects multiple inward
currents in addition to ICaL, such as the late sodium current (Xie
et al., 2009), but modification of ICaL alone was able to eliminate
EADs.
The mechanistic basis for the observed behavior was
established in earlier work describing a window current region
between −40 and 0mV (January and Riddle, 1989) where
the steady-state activation and inactivation curves overlap. In
this region, a fraction of the L-type Ca2+ channels are not
inactivated and available for possible reactivation and generation
of an EAD. A positive shift in the steady-state activation curve
reduces this window region and eliminates EADs. In their
later work, Madhvani et al. systematically perturbed all ICaL
model parameters and measured the consequences to EAD
formation, confirming that parameter changes that reduced
the window current region (depolarizing shifts to steady-state
activation, or hyperpolarizing shifts to steady-state inactivation)
were highly effective at EAD prevention (Madhvani et al.,
2015). Based on these observations, the authors identified the
purine analog Roscovitine, originally developed as an anti-cancer
agent, as a promising anti-arrhythmic due to its ability to
decrease the window current through a reduction to the late
component of ICaL. Preliminary work has shown Roscovitine did
indeed abolish EADs in myocytes and terminated ventricular
tachycardia/fibrillation in whole rat hearts (Karagueuzian et al.,
2017), supporting its therapeutic potential. Notably, this work
illustrates a new paradigm in the search for new classes of
anti-arrhythmic drugs.
Using a similar approach to the ICaL studies, Altomare
et al. investigated the human ether-a-go-go related gene (hERG)
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FIGURE 1 | Using dynamic patch clamp to reveal drug targets and systematically test computational models. (A) Schematic of the dynamic model clamp
configuration. (B) Rabbit ventricular myocytes produce EADs during hydrogen peroxide exposure at a pacing cycle length of 5 s at 37◦C (middle). Replacement of
ICaL with a virtual conductance through dynamic clamp after block with nifedipine recapitulates appearance of EADs (middle). By varying the half-maximal of activation
by 5mV, EADs are abolished (bottom). Adapted with permission (Madhvani et al., 2011). (C) Prediction of a 40% increase or decrease of different cardiac currents
based on a computational model of a ventricular guinea pig cardiomyocyte are tested with dynamic clamp, revealing a substantial mismatch. Adapted with permission
(Devenyi et al., 2017).
channel responsible for the rapid portion of the delayed
rectifier K+ current (IKr) (Altomare et al., 2015). Mutations
and drug perturbations to IKr result in abnormal repolarization,
clinically highlighted by long- or short- QT syndrome. The
authors examined how IKr biophysical properties influenced
APD and its temporal variability by blocking and subsequently
replacing native IKr in guinea pig ventricular cardiomyocytes
using dynamic clamp. The modeled current was shown to
recover control AP parameters adequately, which reveals the
properties described in the model are sufficient to describe the
contribution of IKr to APD and its stability. The voltage and
time dependent properties of IKr were systematically perturbed,
and then compared to control and drug block conditions. This
approach allowed a detailed examination of the consequences
of each current property in isolation. The study showed both
APD and its variability were most sensitive to changes to steady-
state inactivation. Alternatively, while steady-state activation had
little impact on APD, significant changes to APD variability
were observed. This suggests that variability in APD, rather than
mean APD, may be more sensitive in detecting IKr-dependent
repolarization abnormalities.
Dynamic clamp has also been used successfully in studies of
the transient outward K+ current (Ito), where dynamic clampwas
used to vary Ito conductance in ventricular (Dong et al., 2006,
2010; Nguyen et al., 2015) and atrial cardiomyocytes (Workman
et al., 2012). Given the fact existing Ito blocking drugs are non-
selective (Ridley et al., 2003; Aréchiga-Figueroa et al., 2010),
these studies provided important insight into the relationship
between Ito and the morphology and duration of the AP. Dong
et al. sought to understand the impact of Ito on the mechanical
properties of cardiomyocytes. Ito is responsible for the presence
of the characteristic phase-1 notch of the AP, and conflicting
evidence suggested notch prominence can either increase or
decrease ICaL, respectively, enhancing or reducing contraction.
Canine ventricular epicardial myocytes are characterized by a
prominent phase-1 notch, which endocardial myocytes generally
lack (Antzelevitch et al., 1991). By swapping Ito conductance
levels of both cell-types using dynamic clamp, Dong et al. found
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that endocardial cells in which the small native Ito was substituted
by a larger epicardial-like Ito displayed diminished contractility,
and demonstrated that Ito acts as a negative regulator of
contractility through reduction of ICaL peak magnitude (Dong
et al., 2010).
Workman et al. investigated the influence of Ito on atrial
arrhythmogenesis, a topic which was unclear due to the lack
of Ito specific drugs (Workman et al., 2012). Reduction of
Ito through dynamic clamp revealed AP prolongation, and
additional β-adrenergic stimulation evoked EADs. Ito increase
or exposure to the β-blocker atenolol prevented EAD formation.
This suggests Ito enhancement holds promise in arrhythmia
prevention, at least in the atrium. On the other hand, the dynamic
clamp study by Nguyen et al. showed that Ito enhancement
potentiated EADs in rabbit ventricular myocytes with reduced
repolarization reserve, i.e., the intrinsic redundancy against
excessive APD (Roden, 1998). By affecting the early AP phases, Ito
augmentation can alter other voltage-dependent repolarization
currents, leading to decreased late repolarization reserve and
increased EAD formation (Nguyen et al., 2015).
It is important to note that the dynamic clamp technique
suffers from a major limitation, i.e., the lack of ion selectivity in
the current injection. Given physiological intracellular solutions
contain predominantly K+, dynamic clamp of ICaL current will
be carried mainly by K+, and not Ca2+. Thus, the simulated
conductance—which should be Ca2+-dependent per se, is unable
to trigger secondary intracellular Ca2+ release and contraction.
In an attempt to compensate for this limitation, Madhvani et al.
simulated the intracellular Ca2+ transient, which was then fed
back into the ICaL model (Madhvani et al., 2011, 2015), whereas
Devenyi et al. included ion selectivity in their simulations
(Devenyi et al., 2017). While especially true for Ca2+ due to its
major role as a secondary messenger, caution should be applied
when interpreting results of virtual conductance injection, as
transient changes in intracellular concentrations can affect ion
channel behavior.
Improvement of Cardiac Computational
Models
The Comprehensive in vitro Proarrhythmia Assay (CiPA)
initiative seeks to introduce a new cardiac drug safety testing
paradigm that combines in vitro drug effects on multiple ion
channels, computational modeling of cardiac currents and AP,
and the use of human stem-cell derived cardiomyocytes (Sager
et al., 2014; Colatsky et al., 2016). Computational modeling has
proven to be a vital tool in cardiac arrhythmia research, and is
expected to be instrumental in the future pipeline in drug testing.
Confidence in model accuracy is directly tied to dynamic clamp
results, as errors in the formulation of the mathematical model
used can skew results. However, this limitation can be exploited
because only accurate models can fully rescue behavior after drug
block.
Ravagli et al. compared two computational models of the
hyperpolarization-activated funny current, If (Ravagli et al.,
2016), which plays a major role in the pacemaker activity
current of sinoatrial node (SAN) cells. The authors used a
dynamic clamp rescue experiment, where ivabradine was used
to partially block If current, and a dynamic clamp injected
model current was used to rescue control behavior. They showed
one model significantly outperformed the other by restoring
spontaneous activity in SAN cells, identifying the more accurate
mathematical formulation of their experimental data. Bartolucci
et al. used this strategy to validate an optimized formulation
of the IKr current (Bartolucci et al., 2015). The original Luo-
Rudy model (Luo and Rudy, 1994), derived from voltage clamp
step protocols (Sanguinetti and Jurkiewicz, 1990), fit poorly
to their experimentally measured IKr current data obtained
with AP clamp. After optimization to the AP clamp data,
their new model strongly diverged from the widely used Luo-
Rudy formulation and fully reversed IKr block during dynamic
clamp.
Devenyi et al. used dynamic clamp to artificially scale multiple
cardiac currents in guinea pig ventricular myocytes using a
single whole cell model (Devenyi et al., 2017). Altogether,
this amounted to a rapid and efficient testing of multiple
computationally-based hypotheses within the same cell under
static conditions. By comparing their experimental results of
the current perturbations to the predicted results from the
computational model, the authors noted significant discrepancies
(Figure 1C). First, the basal APD was shorter, and second,
current perturbations in the experiment were generally larger
than predicted by the model. The authors then used the new
experimental data to reparameterize the model through unbiased
fitting with a genetic algorithm, yielding a new model that
could recapitulate the experimental data well. Interestingly, while
the original model had a large ratio between the slow (IKs)
and rapid (IKr) portions of the delayed rectifier K
+ current,
the fitting consistently reversed this ratio. This finding was
then verified experimentally, and further in-silico investigation
into the consequences to cardiac arrhythmia showed IKs is
better able to prevent EADs during increased L-type Ca2+
current.
These studies illustrate how dynamic clamp can be used
to experimentally validate computational models, which are
typically built from heterogenous data sets spanning numerous
experiments, under consistent conditions. Thereafter, new data
can be used to further refine the models and advance mechanistic
understanding.
DRUG SAFETY TESTING PLATFORMS
Dynamic clamp has also been utilized in the development
of new assays for assessment of drug proarrhythmic risks.
The current regulatory framework used to prevent approval
of drugs with the potential to induce TdP is focused on two
main areas: the propensity of the drug to block the hERG
channel in vitro, and whether the drug prolongs the QTc
interval of the ECG. Though largely successful at preventing
proarrhythmic drugs from entering the market, the approach
has been criticized due to its low specificity, as hERG block
and QT prolongation do not always carry torsadogenic risk
(Sager et al., 2014; Colatsky et al., 2016). Consequently, it is
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generally agreed that many promising drugs that may have little
arrhythmogenic risk have their development terminated due
to failing either criteria. As mentioned previously, the CiPA
initiative considers human stem-cell derived cardiomyocytes a
key component in future drug safety assays (Sager et al., 2014;
Colatsky et al., 2016), and dynamic clamp has been used to
address key limitations.
Human induced pluripotent stem cell derived cardiomyocytes
(hiPSC-CMs) are being used as an alternative to traditional
animal models, cell lines, and heterologous expression systems
in the study of cardiac electrophysiology mechanisms and drug-
induced arrhythmia. Due to the inherent difficulty in obtaining
human cardiac tissue for study, hiPSC-CMs may provide an
accessible source of human cell lines and includes the additional
capacity to produce patient-specific lines. However, as with
human embryonic stem cell derived cardiomyocytes, hiPSC-CMs
exhibit an immature phenotype. These cells are stereotypically
characterized by spontaneous activity, elevated maximum
diastolic potentials, low maximum upstroke velocity, and highly
variable APD (Hoekstra et al., 2012). A major contributing
factor for these issues is hiPSC-CMs lack of the inward
rectifying K+ current (IK1), which plays a major role maintaining
a stable resting potential in quiescent cardiomyocytes (Doss
et al., 2012). The lack of IK1 is a cumulative issue, in that
a generally depolarized membrane potential influences other
cardiac currents, such as lowering the availability of fast
Na+ channels due to inactivation, which reduces upstroke
velocity.
Bett et al. implemented a dynamic clamp based approach to
resolve the immaturity issue in hiPSC-CMs through the addition
of a virtual IK1 current (Bett et al., 2013). The original erratic AP
morphology of hiPSC-CMs (Figure 2A) was transformed to an
AP profile similar to those seen in adult human cardiomyocytes
(Figure 2B), with a stable resting membrane potential and fast
upstroke velocity. Seeking to test the impact of the dynamic
clamp transformation in response to drug perturbation, hiPSC-
CMs were exposed to the Ca2+ agonist BayK-8644 at room
temperature. Without dynamic clamp, drug addition ceased
spontaneous AP generation (Figure 2C) most likely due to BayK-
8644 induced Ca2+ loading. This is in stark contrast to what is
expected from ventricular cardiomyocytes in humans and other
mammalian species, where an increase in depolarizing Ca2+
currents is expected to increase APD and abnormal activity, such
as EADs.With IK1 dynamic clamp, however, APD prolongation is
evident in stimulated APs (Figure 2D). This illustrates that while
hiPSC-CMs are sensitive to BayK-8644, lack of IK1 can mask the
relevance of drug effects.
Building upon this work, Putten et al. used multiple IK1
models in their dynamic clamp experiments to examine the
impact of varying degrees of rectification (Meijer van Putten
et al., 2015), a biological feature of the IK1 current due to
differential expression of the channel (Kir2.x) subunits (Wang
et al., 1998). Additionally, IK1 channelopathies were investigated
by modifying their Kir2.1 model to represent gain-of-function
and loss-of-function mutations. The gain-of-function mutation
was based on the E299V mutation associated with short QT
syndrome 3, and the loss-of-function mutation was based
on the heterozygous dominant-negative mutation in KCNJ2
associated with Andersen-Tawil syndrome. The top panel of
Figure 2E plots the different current-voltage relationships of the
modified models. The bottom panel of Figure 2E shows the
corresponding APs when these models are used in the calculation
of the virtual IK1 current during dynamic clamp. Consistent
with short QT, the gain-of-function mutation significantly
decreased APD, while the loss-of-function had only a marginal
effect.
More recently, hiPSC-CM studies augmented with IK1
dynamic clamp have provided insight into cardiac abnormalities
such as Brugada syndrome (Veerman et al., 2016), long QT
syndrome (Rocchetti et al., 2017), and familial atrial fibrilliation
(Marczenke et al., 2017). While ion channel dysfunction has
been associated with Brugada Syndrome, mainly the cardiac
fast Na+ current, Veerman et al. found no clear cellular
electrophysiological abnormalities in patient-derived hiPSC-
CMs, suggesting that other factors, such as fibrosis, could also
be underlying mechanisms (Veerman et al., 2016). Rocchetti
et al. recently studied hiPSC-CMs derived from a long QT
patient carrying a heterozygous mutation in one of the
three calmodulin encoding genes (Rocchetti et al., 2017). The
patient-specific cells exhibited prolonged APD and failure to
shorten with increased pacing rate, which the study linked
to impairment of Ca2+-dependent inactivation of ICaL. The
ICaL blocker verapamil reversedmutation-induced repolarization
abnormalities. Marczenke et al. explored the role of mutations
of the KCNA5 gene, encoding the channel responsible for
the ultrarapid delayed rectifier K+ current, in familial atrial
fibrillation (Marczenke et al., 2017). The authors generated
a functional KCNA5 knockout hiPSC-CM line combining
CRISPR/Cas9-mediated mutagenesis and atrial- or ventricular-
specific differentiation through manipulation of retinoic acid
signaling (Devalla et al., 2015). They observed a strictly atrial-
specific disease phenotype, where atrial KCNA5 knockout hiPSC-
CMs exhibited prolonged APD and EADs at low stimulation
frequencies vs. insignificant changes in the ventricular variant.
These works highlight the potential of hiPSC-CMs in cardiac
patient-specific and subtype-specific disease modeling.
IK1 dynamic clamp is becoming more common to hiPSC-CM
studies to reduce variability in experimental metrics, eliminate
spontaneity due to elevated resting membrane potential, and
yield a more physiological relevant phenotype. Verkerk et al.
systematically analyzed the impact of IK1 dynamic clamp
on AP characteristics in atrial and ventricular hiPSC-CMs,
and provided an in-depth comparison of the methodology
and experimental variability of the studies discussed above
(Verkerk et al., 2017). While IK1 dynamic clamp appears
to reduce the variability of most AP parameters, enthusiasm
of reducing the large experimental variability of hiPSC-CMs
is tempered by the observation that APD variability is not
affected. However, elimination of spontaneous depolarizations
allows for stimulus at static frequencies, permitting investigation
into rate-dependence. More importantly, static pacing reduces
beat-to-beat variability, granting a greater ability to detect
AP parameter changes. Verkerk et al. also investigated the
impact of different mathematical formulations of the injected
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FIGURE 2 | Addressing the immature electrophysiological phenotype of hiPSC-CMs. General lack of the IK1 current in hiPSC-CMs plays a major role in their immature
phenotype, which was compensated for through IK1 dynamic clamp. (A) Spontaneous and erratic activity is typical of hiPSC-CMs (average resting potential = −63 ±
5.8mV, n = 21). (B) After injection of a virtual IK1 current via dynamic clamp, cells become quiescent and produce adult-like stimulated APs (average resting potential
= −84 ± 0.1, n = 21). (C) When exposed to the Ca2+ agonist BayK-8644, increased Ca2+ loading terminated spontaneous AP generation. (D) Exposure of
BayK-8644 along with IK1 dynamic clamp prolonged APD compared to (B). (A–D) adapted with permission (Bett et al., 2013). (E) Top panel, current to voltage
relationships of IK1 models representing wild-type Kir2.1, loss-of-function mutation, and gain-of-function mutation. Corresponding AP morphology during dynamic
clamp injection of hiPSC-CMs of each model is shown in the bottom panel. Adapted with permission (Meijer van Putten et al., 2015).
IK1 current, by comparing the models used in several studies
discussed previously (Bett et al., 2013; Meijer van Putten et al.,
2015; Rocchetti et al., 2017). Not surprisingly, the parameter
selection of IK1 current density and kinetics can influence
relevant AP metrics. Conversely, the flexibility inherent to model
modification provides a means to tailor the IK1 current to specific
cell types, such as ventricular or atrial.
The low throughput of dynamic clamp is a major limitation to
its use as part of a drug testing hiPSC-CM platform. Techniques
to increase maturation and IK1 density, such as 3D culturing
(Lemoine et al., 2017) and adenovirus-mediated overexpression
of IK1 (Vaidyanathan et al., 2016), may circumvent the need for
dynamic clamp, but are currently not widely used. Automated
patch clamp offers a possible route to increase throughput, but
brings a new set of issues, such as interfacing with proprietary
equipment and the use of single suspended cells. In a promising
recent advance, Goversen et al. have successfully combined IK1
dynamic clamp with automated patch clamp of hiPSC-CMs,
suggesting the feasibility of high-throughput application as a
drug testing platform (Goversen et al., 2017).
In summary, dynamic clamp has been utilized in a number
of exciting studies to address some of the inherent limitations
of hiPSC-CMs, suggesting a promise as a component of safety
pharmacology testing. Furthermore, the ability to modify the
underlying mathematical models to examine channelopathies
expands the capabilities of this platform.
CONCLUSION
By coupling mathematical models with biological experiments,
dynamic clamp has provided a powerful tool in the search
for potential anti-arrhythmic therapies through model-
based perturbations, enhanced hiPSC-CMs as a platform for
pharmacological safety testing, and used to clarify and improve
mathematical models of cardiac electrophysiology. Dynamic
clamp allows fine manipulation of numerous parameters like
in-silico studies, but is performed in the context of experimental
biology. This approach has enabled investigators to test
theoretical perturbations in real-time and in live cells, and the
power of this technique is represented by the broadness seen
in the studies discussed here. It is expected dynamic clamp
will continue to elucidate the mechanisms underlying cardiac
arrhythmia and identify novel drug targets, and could evolve
into a high-throughput assay, e.g., on automated patch clamp
platforms to improve maturity of hiPSC-CMs.
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